Opendata, web and dolomites

oWBI

Osmotic Wearable Bolus Injector (oWBI) for viscous drug delivery

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 oWBI project word cloud

Explore the words cloud of the oWBI project. It provides you a very rough idea of what is the project "oWBI" about.

97m    significantly    doses    9bn    86    pharmaceutical    170    seeking    ed    flexible    injection    company    region    achievement    administration    drug    closer    dominated    nature    osmotic    actively    disposable    2020    biologically    worn    accumulated    self    unlike    components    subcutaneous    business    formulations    companies    onto    trend    migrate    mechanical    profitability    strategy    convenient    force    pressure    moving    deals    dose    aps    attractive    assist    scj    2015    competitor    bearing    successful    75    body    paying    paired    ing    viscosity    combination    injectors    eco    remarkably    performance    class    bolus    with    medication    subcuject    synthetic    wearable    wbi    sc    intravenous    depending    medical    prefilled    multiple    lower    optimal    drugs    electronic    market    commercialize    profit    disease    device    completion    licensing    segment    customization    2025    coming    cagr    grow    wbis    larger    establishing    predictable    patient   

Project "oWBI" data sheet

The following table provides information about the project.

Coordinator
SUBCUJECT APS 

Organization address
address: NORDRE STRANDVEJ 119
city: HELLEBAEK
postcode: 3150
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Denmark [DK]
 Project website https://subcuject.com/
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.2.1.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Information and Communication Technologies (ICT))
2. H2020-EU.2.3.1. (Mainstreaming SME support, especially through a dedicated instrument)
 Code Call H2020-SMEINST-1-2016-2017
 Funding Scheme SME-1
 Starting year 2018
 Duration (year-month-day) from 2018-02-01   to  2018-04-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    SUBCUJECT APS DK (HELLEBAEK) coordinator 50˙000.00

Map

 Project objective

With more drugs coming onto the market as combination products, i.e. drug products paired with delivery devices pharmaceutical companies are paying closer attention to integrated delivery systems. Due to: 1) the trend in the change in drug formulations, in order to migrate from intravenous to a more cost-effective and convenient subcutaneous (SC) drug administration; and 2) the trend in moving from synthetic derived drugs to biologically drugs that are more complex and have higher viscosity and therefore require delivery of larger doses; resulted in the need for a new class of injection devices - wearable bolus-injectors (WBIs). WBIs are prefilled, disposable devices that are worn on the body of a patient during the SC self-administration of a large dose of medication. The WBI market is estimated to grow in CAGR of 170% between 2015 – 2020 and achieve €6.9Bn by 2025, and pharmaceutical companies are actively seeking for reliable and cost-effective WBIs, providing optimal injection performance at an attractive unit cost and low cost of customization.

Subcuject ApS (SCJ) is a medical device company set to commercialize a new class of WBIs - Subcuject - that makes use of the simple, predictable and strong force of nature: osmotic pressure. Unlike the current WBIs, Subcuject is fully mechanical, bearing no electronic components, resulting in a more flexible, reliable and eco-friendly device at a remarkably lower cost than competitor’s (75 - 86% cost reduction).

SCJ business strategy is based on establishing multiple licensing deals (depending on the drug type, disease, region) with pharmaceutical companies. The Subcuject device is expected to significantly enhance SCJ’s profitability, with an expected accumulated profit of €97M, 5 years after project completion. Moreover, the successful achievement of the project objectives will assist SCJ to be a leading company in the WBI device segment in a market today dominated by U.S. companies.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "OWBI" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "OWBI" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.2.1.1.;H2020-EU.2.3.1.)

Assist (2015)

Telocate ASSIST – Development and marketing of an acoustic solution for localization and navigation of people in buildings using the smartphone

Read More  

Gestoos (2017)

The first Behavior Recognition Open Platform

Read More  

NeuroPsyCAD (2017)

Artificial Intelligence for early and accurate neuropsychiatric diagnosis

Read More